WHAT'S NEW:
The Following newsletters and reports are currently available from the FCDS website:
• 2004 FCDS DATA ACQUISITION MANUAL (Under the downloads)
  FCDS will not be providing hard copies to any facility or contractor.
• FCDS REGISTER Vol. 24
• 6/24/2004:
  FCDS CHANGES FOR HOSPITALS SUBMITTING FULL CANCER ABSTRACTS FOR NAACCR V10.1
  (Does not pertain to Pathology Data or Radiation Therapy ID Data)

On the Web:
• CS SCHEMA “ERRATA” FOR THE PRINTED MANUAL, PART 2
  http://www.cancerstaging.org/cstage/csreplacemen.pdf
• COLLABORATIVE STAGING MANUAL AND CODING INSTRUCTIONS
  http://seer.cancer.gov/tools/collabstaging/

Happy Labor Day

FLORIDA CANCER DATA SYSTEM
SEPTEMBER 2004 MONTHLY MEMO

Ovarian Cancer
National Cancer Institute website:
http://cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/healthprofessional/allpages

Cellular Classification
The following is a list of ovarian epithelial cancer histologic classifications.

• Serous cystomas:
  ■ Serous benign cystadenomas
  ■ Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (low potential or borderline malignancy)
  ■ Serous cystadenocarcinomas

• Mucinous cystomas:
  ■ Mucinous benign cystadenomas
  ■ Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (low potential or borderline malignancy)

• Endometrioid tumors (similar to adenocarcinomas in the endometrium):
  ■ Endometrioid benign cysts
  ■ Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (low malignant potential or borderline malignancy)
  ■ Endometrioid adenocarcinomas

• Clear cell (mesonephroid) tumors:
  ■ Benign clear cell tumors
  ■ Clear cell tumors with proliferating activity of the epithelial cells and nuclear abnormalities, but with no infiltrative destructive growth (low malignant potential or borderline malignancy)

(Continued on page 2)

NCDB EDITS ARE ADAPTED TO BETTER FIT WITH STATE REQUIREMENTS

Edit requirements for data submitted to NCDB for the Fall 2004 Call for Data slated to begin October 4, 2004, have been slightly modified to better coordinate with the data collection requirements of some state central registries. As originally posted, the NCDB edits required that Collaborative Stage fields be blank for all cases diagnosed prior to 2004. Because some states are requiring those items to be completed for cases currently being abstracted, regardless of the diagnosis date, NCDB will not apply the edits requiring blanks for pre-2004 cases. The purpose of this action is to accommodate software providers that might otherwise need to create competing forms of submission files for the NCDB and some states, in order to smooth the submission process for registries regardless of their software services. The revised information, for registrars and software providers who wish to begin testing their data for the next submission, is posted on the NCDB Web page at http://www.facs.org/cancer/ncdb/index.html. The updated files are identified on the Web page by the date indicator “7/29/04.”
September 10, 2004

TO: All Facility Registrars and Abstractors Submitting Full Cancer Abstracts
FROM: Jill MacKinnon
RE: September 30th Reporting Deadline

September 30th is right around the corner and this date marks several important revisions to the FCDS data processing. I have summarized the revisions below:

**Case Reporting**: September 30th is the reporting deadline for your 2003 cases. The Department of Health must be notified of any facility that is delinquent in submitting their 2003 cases. Secondly, this is implementation date for NAACCR v10.1. After the deadline, records submitted in the current NAACCR v10 will no longer be accepted. The implications of v10.1 are that any case submitted on or after October 1st must be submitted in the new format and must have all collaborative staging fields completed, regardless of the diagnosis date.

**Pending Records**: The v10.1 conversion in October will also affect cases in the pending file which are awaiting correction or documentation for force. These records must be corrected by September 30th. If they are not, the records must be resubmitted in v10.1 with all the collaborative staging fields complete. Please send all the corrections and force documentation to your Field Coordinator immediately.

**Batch Upload Revisions**: In addition to implementation of national standards, FCDS will implement ‘real time edits’ for all batch up-loads. That is, immediately upon uploading a batch, your records will undergo the full series of inter and intra-item edits checks. Once all records in the batch have been edited, a message will be returned to you instructing you to download the discrepancy journal. If all records successfully pass the edits, the batch will be accepted and the discrepancy journal will reflect this. If any record fails an edit, the entire batch will be rejected. The discrepancy journal will reflect which record(s) failed and a description of the error(s). The facility must correct the record on their system and resubmit the batch. This process must continue until all records successfully pass the edit process.

The only records that will be accepted in spite of an error are those records that have an ‘over-rideable’ discrepancy. That is, a record that does not satisfy national edit criteria but will have the opportunity to be ‘forced’ into the system with appropriate documentation from the facility. These records will remain in the FCDS pending file until the appropriate documentation is received and accepted. The discrepancy journal will reflect which records failed and based on the error, what documentation is necessary.

Should you have any questions please contact your Field Coordinator.

Thank you.
Clear cell cystadenocarcinomas

- Unclassified tumors that cannot be allotted to one of the above groups
- No histology
- Other malignant tumors (malignant tumors other than those of the common epithelial types are not to be included with the categories listed above)

(Refer to the PDQ summary on Ovarian Low Malignant Potential Tumor Treatment on the National Cancer Institute website at http://cancer.gov/templates/doc.aspx?viewid=d0360d63-9af5-4fb1-bb06-9d8b805d7130&version=1 for more information.)

Stage Information

In the absence of extra-abdominal metastatic disease, definitive staging of ovarian cancer requires laparotomy. The role of surgery in patients with stage IV disease and extra-abdominal disease remains to be established. If disease appears to be limited to the ovaries or pelvis, it is essential at laparotomy to examine and biopsy the diaphragm, both paracolic gutters, the pelvic peritoneum, para-aortic and pelvic nodes, and infracolic omentum, and to obtain peritoneal washings.[1]

In addition, invasion of the bladder and bowel needs to be taken into consideration, and a preoperative intravenous pyelogram and barium enema may be useful to evaluate the urinary tract and large bowel.

The serum CA 125 level is valuable in the follow-up and restaging of patients who have elevated CA 125 levels at the time of diagnosis.[2-4] While an elevated CA 125 level indicates a high probability of epithelial ovarian cancer, a negative CA 125 level cannot be used to exclude the presence of residual disease.[5] CA 125 levels can also be elevated in other malignancies and benign gynecologic problems such as endometriosis, and CA 125 levels should be used with a histologic diagnosis of epithelial ovarian cancer.[6,7]

The Federation Internationale de Gynecologie et d’Obstetrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging.[8,9]

Stage I

Stage I ovarian cancer is limited to the ovaries.

- Stage IA: Tumor limited to 1 ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.*
- Stage IB: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings.*

* [Note: malignant ascites is not classified. The presence of ascites does not affect staging unless malignant cells are present.]

Stage II

Stage II ovarian cancer is tumor involving 1 or both ovaries with pelvic extension and/or implants.

- Stage IIA: Extension and/or implants on the uterus and/or fallopian tubes. No malignant cells in ascites or peritoneal washings.
- Stage IIB: Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings.
- Stage IIC: Pelvic extension and/or implants (stage IIA or IIB) with malignant cells in ascites or peritoneal washings.

Different criteria for allotting cases to stages IC and IIC have an impact on diagnosis. In order to evaluate this impact, it would be of value to know if rupture of the capsule was (1) spontaneous or (2) caused by the surgeon, and if the source of malignant cells detected was (1) peritoneal washings or (2) ascites.

Stage III

Stage III ovarian cancer is tumor involving 1 or both ovaries with microscopically confirmed peritoneal implants outside the pelvis. Superficial liver metastasis equals stage III. Tumor is limited to the true pelvis but with histologically verified malignant extension to small bowel or omentum.

- Stage IIIA: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor).
- Stage IIIB: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension.
- Stage IIIC: Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis.

Stage IV

Stage IV ovarian cancer is tumor involving 1 or both ovaries with distant metastasis. If pleural effusion is present, there must be positive cytologic test results to designate a case to stage IV. Parenchymal liver metastasis equals stage IV.

References

Treatment Option Overview


Stage I Ovarian Epithelial Cancer

Standard treatment options:

1. If the tumor is well or moderately well differentiated, total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy is adequate for patients with stage IA and IB disease. The undersurface of the diaphragm should be visualized and biopsied; pelvic and abdominal peritoneal biopsies and pelvic and para-aortic lymph node biopsies are required and peritoneal washings should be obtained routinely.[1] In selected patients who desire childbearing and who have grade I tumors, unilateral salpingo-oophorectomy may not be associated with high risk of recurrence.[2]

2. If the tumor is grade III, densely adherent, or stage IC, the chance of relapse and subsequent death from ovarian cancer is substantial (up to 20%), although the importance of tumor rupture if it is the only adverse characteristic is not clear.[3-5] Several treatment approaches that have been taken in such patients are listed below

- Intraperitoneal P-32 or radiation therapy.[1,6,7]
- Systemic chemotherapy.[1,6,8-10]
- Total abdominal and pelvic radiation therapy.[1,12]
- Careful observation without immediate treatment in selected patients (watchful waiting).

References


Stage II Ovarian Epithelial Cancer

Standard treatment options:

Surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy and tumor debulking to remove all or most of the tumor. If there is no clinically apparent disease outside of the pelvis (Continued on page 5)
and systemic therapy is contemplated, additional staging procedures, while possibly influencing choice of therapy, may not influence survival.[1] If there is no clinical residual disease, the undersurface of the diaphragm should be visualized and biopsied and the abdominal peritoneum sampled; selective pelvic and para-aortic node sampling is required. The options for further treatment include:

1. If minimal postsurgical residual para-aortic node sampling is required.

**References**


**Stage III and IV Ovarian Epithelial Cancer**

Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (For more information refer to the PDQ summary on Levels of Evidence located on the NCI website at http://cancer.gov/templates/doc.aspx?viewid=2b9oa8c6-7202-4728-9dd0-77ca57170044&version=1.)

**Standard treatment options:**

**Surgery**

Surgery has been used as a therapeutic modality and also to adequately stage the disease. Surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy and debulking of as much gross tumor as can safely be performed. While primary cytoreductive surgery may not correct biologic characteristics of the tumor, there is considerable evidence that the volume of disease left at the completion of the primary surgical procedure is related to patient survival.[1] A literature review showed that patients with optimal cytoreduction had median survival of 39 months compared with survival of only 17 months in patients with suboptimal residual disease.[1] However, results of a retrospective analysis of 349 patients with postoperative residual masses less than or equal to 1 cm suggested that patients who present at the outset with large-volume disease and achieve small-volume disease by surgical debulking have poorer outcomes than similar
EDUCATION AND TRAINING

CANCER REGISTRATION AND SURVEILLANCE TRAINING PROGRAMS

The Fullmer Institute is pleased to announce:

- **PRINCIPLES AND PRACTICE OF CANCER REGISTRATION AND SURVEILLANCE**
  November 1-5, 2004 (and more dates in 2005!)

- **ADVANCED TOPICS IN CANCER REGISTRATION AND SURVEILLANCE**
  October 18-20, 2004  
  May 4-6, 2005  
  August 10-12, 2005

For further information and registration visit the Fullmer Institute website, http://www.fullmerinstitute.org.

PRINCIPLES OF ONCOLOGY FOR CANCER REGISTRY PROFESSIONALS

December 6 - 10, 2004  
Bolger Center for Leadership Development  
Potomac, Maryland  
Registration fee: $695.00*

*The registration fee is reduced for participants who stay at the conference center.

For further information on this program please visit the National Cancer Institute (NCI) website at: http://seer.cancer.gov/training/oncology/.

2005 CTR EXAM CONTENT

http://www.ctrexam.org/

The content of the 2005 CTR Examinations will be drawn in part from the publications of several national standard-setting organizations, including:

- International Classification of Diseases for Oncology 3rd Edition (ICD-O-3);
- Facility Oncology Registry Data Standards "FORDS: Revised for 2004";
- CoC Cancer Program Standards 2004
- Collaborative Staging Manual and Coding Instructions, version 1.0.

The Collaborative Staging (CS) will test on the following data fields and sites.

<table>
<thead>
<tr>
<th>CS DATA FIELDS:</th>
<th>SPECIFIC CS FIELD SITES:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CS Extension</td>
<td>1. Breast</td>
</tr>
<tr>
<td>2. CS Lymph nodes</td>
<td>2. Lung</td>
</tr>
<tr>
<td>3. CS Metastasis</td>
<td>3. Colon Rectal Bladder</td>
</tr>
<tr>
<td></td>
<td>4. Kidney</td>
</tr>
<tr>
<td></td>
<td>5. Melanoma</td>
</tr>
<tr>
<td></td>
<td>6. Ovary</td>
</tr>
<tr>
<td></td>
<td>7. Corpus Uteri (Endometrium)</td>
</tr>
<tr>
<td></td>
<td>8. Pancreas</td>
</tr>
<tr>
<td></td>
<td>9. Thyroid</td>
</tr>
</tbody>
</table>

Please note that Summary Stage 2000 is no longer tested. Plus, the exam content excludes any clarifications posted in the SEER SINQ and Commission on Cancer’s Inquiry and Response system.
patients who present with small-volume disease.[2] It is nevertheless likely that there is gradual improvement in survival with decreasing residual tumor volume. Although the association may not be causal, retrospective analyses, including a meta-analysis of patients receiving platinum-based chemotherapy, have found cytoreduction to be an independent prognostic variable for survival.[3,4]

The value of interval cytoreductive surgery has also been the subject of phase III trials. In the first study, performed by the European Organisation for Research and Treatment of Cancer, patients subjected to debulking after 4 cycles of cyclophosphamide and cisplatin (with additional cycles given later) had an improved survival over patients who completed 6 cycles of this chemotherapy without surgery.[5] [Level of evidence: 1iiB] A similar trial by the Gynecologic Oncology Group (GOG-162 [6]), but using paclitaxel plus cisplatin as the chemotherapy, did not demonstrate any advantage from interval cytoreductive surgery. Wider use of maximal surgical effort at the time of diagnosis by US gynecologic oncologists may be a factor accounting for these divergent results. Although many patients with stage IV disease undergo cytoreductive surgery, whether this improves survival has not been established.[7]

Surgery also has a role in reassessment to determine the extent of residual disease, if any, following the initial (induction) chemotherapy. Historically, second-look laparotomies were routinely performed after completion of chemotherapy for those stage III patients who have a computed tomographic scan not suggestive of residual active disease, who are clinically without evidence of disease, and whose CA 125 is normal. There are no data from randomized trials to show that therapeutic decisions based on results of this procedure alter outcomes for the patient. In a large nonrandomized trial, there was no survival advantage in patients who received a second-look operation as compared to those who did not [8] and the only randomized trial, albeit statistically underpowered, was negative.[9]

Approximately one third of patients found to have macroscopic tumor at second-look surgery achieve complete cytoreduction resulting in microscopic residual disease, approximately one third achieve partial debulking resulting in optimal residual disease, and the remainder are left with bulky tumors. The value of secondary tumor reduction at the time of second-look laparotomy is controversial. Some have reported improved survival in patients who achieve optimal secondary debulking, [10-12] while others report survival benefit for those left with microscopic disease only.[13] Whether the survival benefit of complete secondary cytoreduction is a function of the surgical debulking or a reflection of the characteristics of the tumor that permits complete cytoreduction is not known.[14-16] Since there are no controlled clinical trials that demonstrate a survival advantage for the second-look operation, it is often performed either as part of a clinical trial or when a prescribed second-line therapy is being tested. Finally, reassessment surgery has been linked to the introduction of IP catheters, in order to test the pharmacologically derived concept of IP consolidation with drugs delivered directly into the peritoneal cavity. A number of IP regimens have been tested, and phase III trials have provided support for the validity of this concept.[17]

**Intraperitoneal regimens**

A pharmacologic advantage for this route possibly resulting in an improved outcome pertains only to the minimal or no residual disease setting. Therefore, the extent of residual disease after the initial surgery or at reassessment has been used to guide the development of these treatment strategies. The use of IP radioactive phosphate after negative second-look surgery does not appear to increase overall or disease-free survival rates. [18] Early reports suggested a role for IP chemotherapy [19-21] by demonstrating surgically defined complete response rates and prolonged survival [22] in approximately 25% to 35% of patients with small-volume residual persistent disease after a variety of IP regimens.[21,23] Outcome was particularly favorable in patients defined as platinum-sensitive, a feature indicative of a greater overall responsiveness to other treatments as well. A randomized trial will be necessary to determine whether IP chemotherapy given as consolidation has a survival advantage over alternative second-line therapies. Platinum compounds alone or in combination have received the most attention but nonplatinum drugs have also been studied. For example, the Southwest Oncology Group adopted continuous infusion of floxuridine over mitoxantrone as consolidation for minimal residual disease, in view of the results of a phase II randomized trial.[17]

The use of IP cisplatin as part of the initial up-front approach in stage III optimally-debulked ovarian cancer is supported by the results of 3 randomized clinical trials. These studies tested the role of IP drugs (IP cisplatin in all 3 studies, and IP paclitaxel in the last study) versus the standard IV regimen. In all 3 studies superior progression-free survival was documented favoring the IP arm, and in the 2 fully reported to date, the overall survival was also significantly better in the IP arm.[17] [Level of evidence: 1iiB] However, IP therapy has not been routinely adopted, in part because of issues relating to greater toxicity and inconvenience.[24] Moreover, since 2001 the GOG and International Collaborators have embarked in trials that do not distinguish optimally debulked (<1 cm residuum) versus suboptimally debulked (residuum >1 cm) patients for entry into studies, and do not encourage reassessment after completion of induction regimens.

**Chemotherapy options**

*First-line chemotherapy has been built on 2 premises supported by retrospective analyses and consecutive clinical trials by cooperative groups:*

1. Platinum compounds, up to an “optimal dose-intensity,” represent the core of the treatment (e.g., platinum-based chemotherapy). An initial analysis noted a relationship between survival and dose-intensity of cisplatin.[25]

(Continued on page 8)
However, clinical trials escalating the drug to 100 mg/m2 every 3 weeks did not support an advantage over 50 mg/m2 every 3 weeks, and adopted 75 mg/m2 as the standard.[26,27] Similarly for carboplatin, a large retrospective study suggested improved outcome up to a target area under the curve (AUC) of 5, and then a plateau in effectiveness in spite of increasing drug exposure.[28] Subsequently, a randomized trial comparing carboplatin dosed according to a target AUC of 6 versus a target AUC of 12 yielded similar results.[29]

2. Cisplatin and carboplatin yield equivalent results. Several clinical trials supporting the introduction of carboplatin into the clinic demonstrated it yielded similar results in ovarian cancer as cisplatin. Trials of either platinum in combination with cyclophosphamide [30,31] [Level of evidence: 1iiB] or with paclitaxel [8,32] [Level of evidence: 1iiB] have also shown similar outcomes. Therefore, current efforts are focusing on how a number of drugs with activity against ovarian cancer may be optimally combined with the platinum drugs, either in combination or in sequence.

References

6. Spriggs DR, Gynecologic Oncology Group: Phase III Randomized Study of 24 Hour Versus 96 Hour Infusion of Paclitaxel With Cisplatin in Patients With Suboptimal Stage III or IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer (Summary Last Modified 10/2000), GOG-162, Clinical trial, Closed. [PDQ Clinical Trial]
INFORMATION & NEWS

THE 2004 FCDS DATA ACQUISITION MANUAL
The 2004 FCDS Data Acquisition Manual is available for download from the FCDS website, http://fcds.med.miami.edu under the downloads link.

FCDS will not be providing hard copies to any facility or contractor.

NATIONAL HEALTH INFORMATION AND TECHNOLOGY WEEK
National Health Information and Technology Week, November 7-13, sponsored by AHIMA. The annual event was started 15 years ago to recognize the work of HIM professionals who maintain and protect the health information of individuals nationwide. The theme of this year’s celebration is “Health Information: Powered by Professionals,” and we have prepared a kit to help you plan your week. To access the planning kit online, visit: http://www.ahima.org/hitweek.

CS SCHEMA "ERRATA" PRINTED MANUAL, PART 2

COLLABORATIVE STAGING MANUAL AND CODING INSTRUCTIONS
http://seer.cancer.gov/tools/collabstaging/

The Collaborative Staging Manual and Coding Instructions is published jointly by the SEER Program, the National Program of Cancer Registries of the Centers for Disease Control and Prevention, and the American College of Surgeons Commission on Cancer. The Collaborative Staging System is a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. It provides the codes and coding instructions for the Collaborative Staging System fields for cases diagnosed January 1, 2004 and forward. These fields are now required by all central registries in the US and Canada and all hospitals that report to them.

The Collaborative Staging Manual and Coding Instructions publication is available electronically and can be downloaded from American Joint Committee on Cancer Web site. Or, you may order a printed copy of this book from the SEER website at http://seer.cancer.gov/cgi-bin/pubs/order1.pl?CODING,BOOK,CONV,MONO,CSR,,ABOUT.
1. Question
Surgery of Primary Site--Ovary: What code is used to represent this field when a patient has a history of a previous organ removal and has additional surgery/organ removal for a present cancer (e.g., History of a 1984 hysterectomy and in 2003 has ovarian primary treated with BSO)?

Answer
For cases diagnosed 1/1/2003 and after: Code the Surgery of Primary Site field to 52 [Bilateral salpingo-oophorectomy WITH hysterectomy].

References
SEER Program Code Man, 3rd Ed., pp 14

2. Question
Multiple Primaries--Ovary: Are mucinous cystic tumors of low malignant potential diagnosed in the left ovary in 12/2000 and in the right ovary in 7/2001 considered reportable as two primaries?

Answer
Borderline tumors are not reportable to SEER in 2001. If you are collecting them in your registry, use the following procedure: Exception 1 in the SEER Program Code Manual responds to the issue of processing ovarian tumors. Simultaneously occurring ovarian tumors with a single histology are coded as one primary. In the case you cite, the right ovary primary occurred 7 months after the left ovary primary. This is not simultaneous, so it would be counted as a second primary.

3. Question
Reportability--Ovary: Are borderline ovarian tumors diagnosed in 2001 and later with implants, or "focal microinvasion," or "focus of intraepithelial carcinoma" reportable to SEER?

Answer
Borderline ovarian tumors are not reportable, behavior is /1. If the principal tumor is borderline and there are tumor deposits on other pelvic surfaces, the case remains borderline and non-reportable by SEER rules UNLESS the pathologist makes a definite statement that the tumor deposits are malignant. For borderline ovarian tumors, the following are NOT statements of definite malignancy: "microinvasive," "focus of intraepithelial carcinoma."

4. Question
Primary Site--Ovary/Peritoneum: When ovaries are not found on a resection or if the ovaries removed are negative for malignancy, but the clinician refers to the adenocarcinoma in the pelvis as being an "ovarian" primary, should the primary site be coded as ovary, pelvic peritoneum or unknown?

Answer
Code the Primary Site for both examples to peritoneum [C48.2]. When the physician refers to a case as "ovarian" even though the ovaries are negative or when the histology is an ovarian histology, but the clinician refers to the adenocarcinoma in the pelvis as being an "ovarian" primary, should the primary site be coded as pelvic peritoneum or unknown? Code the Primary Site to where it appears the disease is arising.

References
SEER Program Code Man, 3rd Ed., pp 14

(Continued from page 8)

1693-8, 1994. [PUBMED Abstract]
DEADLINES AND REMINDERS

AMBULATORY CARE CENTERS CANCER REPORTING PROGRAM

On August 11, 2004, FCDS completed the matching of the 2002 outpatient discharges reported by Florida Ambulatory Patient Care Centers’ Finance-Billing/Medical Records Department to the Agency for Health Care Administration (AHCA). All records with principal or secondary diagnoses of cancer were linked to the FCDS database. Only records reported to AHCA but not matched to a FCDS record will appear on the lists titled “AHCA Ambi Unmatched Cancer Records Request.”

On August 13, 2004, FCDS mailed the “AHCA Ambi Unmatched Cancer Records Request” lists for 2002 to the Florida Ambulatory Patient Care Centers. The 2002 listings included patient encounters between January 1, 2002 and December 31, 2002. The centers received notification for cases that were never reported from any other source to FCDS.

Any facility with fewer than 35 cancer cases identified on the “AHCA Ambi Unmatched Cancer Records Request” list need only submit copies of patient records to FCDS for each of the cases on the list. A Batch Transmittal Form must be included with any chart copies submitted. The following reports (if available) from each patient record must be submitted by September 30, 2004: Face sheet, Summary, History & Physical, Operative Reports, Consultation Reports, Pathology Reports, Radiology Reports, Laboratory Reports and all other pertinent reports.

Any facility with greater than 35 cancer cases on the “AHCA Ambi Unmatched Cancer Records Request” list must determine whether or not each of the identified case records must be reported to the FCDS by referring to the FCDS reporting criteria outlined in Section I of the FCDS Data Acquisition Manual. If the case meets the FCDS reporting criteria, a full case abstract must be submitted to FCDS by September 30, 2004. All data submitted to FCDS must be via the encrypted Internet transmission, FCDS IDEA. For further information, visit the FCDS website at http://fcds.med.miami.edu.

FCDS CONVERTING TO NAACCR VERSION 10.1 October 1-15, 2004

FCDS will be converting the state registry database to the NAACCR version 10.1 record layout from October 1, 2004 until October 15, 2004. Data will continue to be accepted through FCDS IDEA during this period.

Due to the conversion, please be aware of the following dates. The dates will affect your workload. Cases received by FCDS on or before September 30, 2004: All abstracts for diagnosis prior to 2004 may continue to be submitted according to the current reporting guidelines and record layout (NAACCR version 10). Cases received by FCDS October 1, 2004 and after: All abstracts regardless of diagnosis date must be submitted according to the new reporting guidelines and new NAACCR version 10.1 record layout (This includes the new data items).

REMINDER:
Effective with NAACCR version 10.1, all Collaborative Staging fields must be completed on ALL cases regardless of date of diagnosis. This includes “historical cases.”

FCDS MAILING INFORMATION

For those facilities and physician office that need to mail the patient(s) medical record, please use our general mailing information listed below:

In order to protect and properly handle all packages, particularly those containing confidential patient information, we ask that US Postal Service mail including Express mail, Priority mail, and Certified mail be sent to FCDS via the PO Box address below:

FCDS/ University of Miami School of Medicine
PO BOX 016960 (D4-11)
Miami, FL 33101

FCDS STREET ADDRESS SHOULD ONLY BE USED FOR COURIER PACKAGES
(Federal Express, UPS, Airborne Express).
FCDS/University of Miami School of Medicine
1550 NW 10 AVE, Room 410
Miami, FL 33136
FLORIDA CANCER DATA SYSTEM
Path Reporting and Radiation Therapy Reporting

Path

Radiation

FLORIDA CANCER DATA SYSTEM
A Joint Project of the Sylvester Comprehensive Cancer Center and the Florida Department of Health
P. O. BOX 016960 (D4-11)
MIAMI, FL 33101

PROJECT DIRECTOR:
Lora Fleming, MD, PhD

ADMINISTRATIVE DIRECTOR:
Jill Mackinnon, CTR

EDITORIAL STAFF:
Mark Rudolph, M.S.
Mayra Alvarez, RHIT, CTR
Melissa K. Williams

CONTRIBUTORS:
Kelly Large, CTR